Clarification of methodology in “Impact of pharmacist's intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low-resource settings”

Abstract

Keywords

Pharmacist carcinoma non-small-cell lung drug interactions

Get full access to this article

View all access options for this article.

References

Akamatsu

Mori

Naito

, et al. Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer 2014 Jan 14: 14–18.

IBM Corp . IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp, 2011.

Lam

Capparelli

Kurzrock

. Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol 2016; 78: 427–432.